৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Resmit (Resmetirom) is a thyroid hormone receptor-beta (THR-β) agonist indicated for the treatment of adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (F2-F3), alongside diet and exercise. It helps reduce liver fat accumulation and supports improvement of liver health.
Resmetirom is a selective THR-β agonist that primarily acts in the liver:
Based on actual body weight:
Administration:
Common side effects include:
Use caution with:
Resmetirom is a novel oral medication classified as a thyroid hormone receptor-beta (THR-β) agonist.
It is specifically designed to treat nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (F2–F3 stages) in adults.
Resmetirom works by activating thyroid hormone receptors in the liver, which improves fat metabolism, reduces liver fat accumulation, and slows fibrosis progression.
It represents the first approved therapy for NASH with fibrosis, offering a targeted treatment option where previously only lifestyle changes and supportive care were available.
The drug is taken orally in tablet form and requires medical supervision with regular liver function monitoring.






First approved therapy for NASH: Resmetirom is the first oral drug specifically approved for nonalcoholic steatohepatitis (NASH) with liver fibrosis (F2–F3).
Reduces liver fat: Improves fat metabolism in the liver, lowering hepatic steatosis.
Slows fibrosis progression: Helps prevent worsening of liver scarring, reducing risk of cirrhosis.
Improves liver function: By reducing fat and fibrosis, it supports healthier liver performance.
Convenient oral dosing: Taken as a tablet, making treatment easier compared to invasive therapies.
Better patient outcomes: Provides a targeted option beyond lifestyle changes, improving quality of life for NASH patients.

